Nuclear Medicine and Biology
Volume 39, Issue 2 , Pages 167-176, February 2012

Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass

  • Yi Wang

      Affiliations

    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    • School of Environment, Tsinghua University, Beijing 100084, P.R. China
  • ,
  • Keunpoong Lim

      Affiliations

    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
  • ,
  • Marc Normandin

      Affiliations

    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
  • ,
  • Xiaojian Zhao

      Affiliations

    • Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
  • ,
  • Gary W. Cline

      Affiliations

    • Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
  • ,
  • Yu-Shin Ding

      Affiliations

    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 203 785 4297; fax: +1 203 785 3107.

Received 19 December 2010; received in revised form 24 June 2011; accepted 15 July 2011. published online 28 October 2011.

Abstract 

Introduction

Glucagon-like peptide 1 (GLP-1) is released in response to food intake and plays an important role in maintaining blood glucose homeostasis. Exendin (9–39), a potent glucagon-like peptide 1 receptor antagonist, has been labeled with In-111 for SPECT imaging. We report here the first radiosynthesis of [18F]exendin (9–39) ([18F]Ex(9–39)) and an evaluation of its potential as a biomarker for in vivo positron emission tomography (PET) imaging of pancreatic β-cell mass (BCM) in rats.

Methods

F-18 label was introduced by conjugation of [18F]4-fluorobenzaldehyde with an Ex(9–39) derivative containing a 6-hydrazinonicotinyl group on the ɛ-amine of Lys27. Positron emission tomography imaging was carried out in Sprague–Dawley rats (five control and five streptozotocin-induced diabetic) and BioBreeding diabetes-prone rats (three at 7 weeks and three at 12 weeks) using the high-resolution research tomograph (HRRT) after 0.187±0.084 mCi [18F]Ex(9–39) administration. Time–activity curves were obtained from pancreas, liver and kidney. Pancreases were assayed for insulin content after the imaging study.

Results

Site-specifically labeled [18F]Ex(9–39) was purified on a G15 open column with radiochemical and chemical purities >98%. Positron emission tomography imaging showed pancreatic standardized uptake value (SUV) peaked at 10 min and plateaued by 50 min to the end of scan (240 min). No correlations of pancreatic SUV with postmortem measures of insulin content were seen.

Conclusions

[18F]Ex(9–39) was successfully prepared and used for PET imaging for the first time to measure pancreatic BCM. The results suggest that derivatization of the Lys27 residue might reduce binding affinity, as evidenced by the absence of specific binding. Exendin analogues radiolabeled at other sites may elucidate the active site required for binding.

Keywords: Glucagon-like peptide 1 (GLP-1), HYNIC, PET imaging, [18F]Exendin (9–39), Pancreatic β-cell mass, Diabetes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(11)00191-0

doi:10.1016/j.nucmedbio.2011.07.011

Nuclear Medicine and Biology
Volume 39, Issue 2 , Pages 167-176, February 2012